✦ LIBER ✦

A 1- and 2-year follow-up study of bowel sound biofeedback as a treatment for irritable bowel syndrome

✍ Scribed by Radnitz, Cynthia L. ;Blanchard, Edward B.

Publisher: Springer-Verlag
Year: 1989
Weight: 257 KB
Volume: 14
Category: Article
ISSN: 1573-3270
DOI: 10.1007/bf00999124

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bowel sound biofeedback as a treatment f

Bowel sound biofeedback as a treatment for irritable bowel syndrome

✍ Radnitz, Cynthia L. ;Blanchard, Edward B. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 544 KB

Behavioral treatment of irritable bowel

Behavioral treatment of irritable bowel syndrome: A 1-year follow-up study

✍ Schwarz, Shirley P. ;Blanchard, Edward B. ;Neff, Debra F. 📂 Article 📅 1986 🏛 Springer-Verlag ⚖ 460 KB

Biofeedback treatment for headaches, Ray

Biofeedback treatment for headaches, Raynaud's disease, essential hypertension, and irritable bowel syndrome: A review of the long-term follow-up literature

✍ Ford, Martin R. 📂 Article 📅 1982 🏛 Springer-Verlag ⚖ 950 KB

Breathing retraining: A three-year follo

Breathing retraining: A three-year follow-up study of treatment for hyperventilation syndrome and associated functional cardiac symptoms

✍ DeGuire, Steven ;Gevirtz, Richard ;Hawkinson, Denise ;Dixon, Kristin 📂 Article 📅 1996 🏛 Springer-Verlag ⚖ 398 KB

ChemInform Abstract: Design and Synthesi

ChemInform Abstract: Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS).

✍ Akira Asagarasu; Teruaki Matsui; Hiroyuki Hayashi; Satoru Tamaoki; Yukinao Yamau 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 15 KB 👁 2 views

Ten-year follow-up of a phase 2 study of

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

✍ Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced‐stage epithelial ovarian cancer (EOC) who were receiving dose‐intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched